JNJ-78306358, a first-in-class bispecific T cell engaging antibody targeting CD3 and HLA-G
Nataša Obermajer(Palo Alto University), Sylvie Laquerre(Johnson & Johnson (United States))
Cited by 5
Related Papers
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition
|Clinical Cancer Research|2011|600
Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
|PLoS ONE|2013|216